INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on December 19, 2022, reporting events occurring on December 13, 2022. The company is incorporated in Nevada and its common stock is registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing details a specific financing event rather than comprehensive financial statements. Key metrics related to this transaction include:
- Total Proceeds: $100,000 received via demand promissory notes.
- Debt Structure: Notes are callable with 10 days' prior written notice, exercisable starting 30 days after issuance.
- Interest Terms: Interest-free until January 31, 2023. Thereafter, 10% annual interest accrues on outstanding amounts.
- Financing Fee: A 10% fee is due on the outstanding principal at maturity.
The filing text does not provide clear values for revenue, operating profit, cash flow, margins, or total liquidity outside of this specific transaction.
Material Changes
The primary material change is the creation of a direct financial obligation through the issuance of related-party debt. The $100,000 in proceeds were sourced as follows:
- $25,000 from Steven Shum, Chief Executive Officer.
- $25,000 from Andax LLC, an entity controlled by Andrea Goren, Chief Financial Officer.
- $50,000 from JAG Multi Investments LLC, a related party to Mr. Goren (who is a beneficiary but does not control investment decisions).
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the new debt instrument. The primary risk associated with this filing is the immediate liquidity obligation, as the notes are demand instruments callable by the lenders after a 30-day waiting period. The company faces a potential cash outflow of principal, accrued interest, and a 10% financing fee if the notes are called or mature.
Investor Verification Checklist
- Verify the company's current cash balance to assess ability to repay the $100,000 principal plus the 10% financing fee ($10,000) if called immediately after the 30-day period.
- Review the full text of Exhibits 4.1, 4.2, and 4.3 for any additional covenants or default provisions not summarized in the 8-K.
- Confirm the status of the related-party transactions to ensure compliance with Nasdaq listing rules regarding related-party disclosures.
- Monitor subsequent filings for any acceleration of the debt or changes in the company's liquidity position.